Literature DB >> 10691865

Incidence, characterization and prognostic significance of chromosomal abnormalities in 640 patients with primary myelodysplastic syndromes. Grupo Cooperativo Español de Citogenética Hematológica.

F Solé1, B Espinet, G F Sanz, J Cervera, M J Calasanz, E Luño, F Prieto, I Granada, J M Hernández, J C Cigudosa, J L Diez, E Bureo, M L Marqués, E Arranz, R Ríos, J A Martínez Climent, T Vallespí, L Florensa, S Woessner.   

Abstract

Recently, a consensus International Prognostic Scoring System (IPSS) for predicting outcome and planning therapy in the myelodysplastic syndromes (MDS) has been developed. However, the intermediate-risk cytogenetic subgroup defined by the IPSS includes a miscellaneous number of different single abnormalities for which real prognosis at present is uncertain. The main aims of this study were to evaluate in an independent series the prognostic value of the IPSS and to identify chromosomal abnormalities with a previously unrecognized good or poor prognosis in 640 patients. In univariate analyses, cases with single 1q abnormalities experienced poor survival, whereas those with trisomy 8 had a higher risk of acute leukaemic transformation than the remaining patients (P = 0.004 and P = 0.009 respectively). Patients with single del(12p) had a similar survival to patients with a normal karyotype and showed some trend for a better survival than other cases belonging to the IPSS intermediate-risk cytogenetic subgroup (P = 0.045). Multivariate analyses demonstrated that IPSS cytogenetic prognostic subgroup, proportion of bone marrow blasts and haemoglobin level were the main prognostic factors for survival, and the first two characteristics and platelet count were the best predictors of acute leukaemic transformation risk. A large international co-operative study should be carried out to clarify these findings.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10691865     DOI: 10.1046/j.1365-2141.2000.01868.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  34 in total

1.  An MLL-SEPT9 fusion and t(11;17)(q23;q25) associated with de novo myelodysplastic syndrome.

Authors:  Lisa M Baumann Kreuziger; Julie Cliff Porcher; Rhett P Ketterling; David P Steensma
Journal:  Leuk Res       Date:  2007-01-23       Impact factor: 3.156

2.  Topography, clinical, and genomic correlates of 5q myeloid malignancies revisited.

Authors:  Andres Jerez; Lukasz P Gondek; Anna M Jankowska; Hideki Makishima; Bartlomiej Przychodzen; Ramon V Tiu; Christine L O'Keefe; Azim M Mohamedali; Denise Batista; Mikkael A Sekeres; Michael A McDevitt; Ghulam J Mufti; Jaroslaw P Maciejewski
Journal:  J Clin Oncol       Date:  2012-02-27       Impact factor: 44.544

Review 3.  Myelodysplastic syndromes.

Authors:  Olatoyosi Odenike; John Anastasi; Michelle M Le Beau
Journal:  Clin Lab Med       Date:  2011-10-10       Impact factor: 1.935

4.  Cytogenetic risk stratification of 417 patients with chronic myelomonocytic leukemia from a single institution.

Authors:  Guilin Tang; Liping Zhang; Bin Fu; Jianhua Hu; Xinyan Lu; Shimin Hu; Ankita Patel; Maitrayee Goswami; Joseph D Khoury; Guillermo Garcia-Manero; L Jeffrey Medeiros; Sa A Wang
Journal:  Am J Hematol       Date:  2014-05-16       Impact factor: 10.047

5.  First Cytogenetic Profile of Omani Patients with de novo Myelodysplastic Syndromes: Comparison with data from Asia, Africa, Europe and North and South America.

Authors:  Achandira M Udayakumar; Nagla Fawaz; Anil Pathare; Shakila Asraf; Mohammed Al-Huneini; Khalil Al-Farsi; Salam Al-Kindi; Murtadha Al-Khabouri
Journal:  Sultan Qaboos Univ Med J       Date:  2017-10-10

6.  Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients.

Authors:  Andrea Pellagatti; Martin Jädersten; Ann-Mari Forsblom; Helen Cattan; Birger Christensson; Emma K Emanuelsson; Mats Merup; Lars Nilsson; Jan Samuelsson; Birgitta Sander; James S Wainscoat; Jacqueline Boultwood; Eva Hellström-Lindberg
Journal:  Proc Natl Acad Sci U S A       Date:  2007-06-18       Impact factor: 11.205

7.  Possibility of the diagnosis of subacute myeloid leukemia for a group of patients with trisomy 8: a report of 34 cases.

Authors:  Yan Zhang; Jing-Ying Qiu; Yue-Yun Lai; Dao-Pei Lu
Journal:  Int J Hematol       Date:  2004-08       Impact factor: 2.490

8.  Trisomy 8 in an allogeneic stem cell transplant recipient representative of a donor-derived constitutional abnormality.

Authors:  Noelle V Frey; Christopher E Leid; Peter C Nowell; Ewa Tomczak; Honore T Strauser; Margaret Kasner; Steven Goldstein; Alison Loren; Edward Stadtmauer; Selina Luger; Elizabeth Hexner; Joanne Hinkle; David L Porter
Journal:  Am J Hematol       Date:  2008-11       Impact factor: 10.047

9.  Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML.

Authors:  Lukasz P Gondek; Ramon Tiu; Christine L O'Keefe; Mikkael A Sekeres; Karl S Theil; Jaroslaw P Maciejewski
Journal:  Blood       Date:  2007-10-22       Impact factor: 22.113

10.  Distinct patterns of mutations occurring in de novo AML versus AML arising in the setting of severe congenital neutropenia.

Authors:  Daniel C Link; Ghada Kunter; Yumi Kasai; Yu Zhao; Tracie Miner; Michael D McLellan; Rhonda E Ries; Deepak Kapur; Rakesh Nagarajan; David C Dale; Audrey Anna Bolyard; Laurence A Boxer; Karl Welte; Cornelia Zeidler; Jean Donadieu; Christine Bellanné-Chantelot; James W Vardiman; Michael A Caligiuri; Clara D Bloomfield; John F DiPersio; Michael H Tomasson; Timothy A Graubert; Peter Westervelt; Mark Watson; William Shannon; Jack Baty; Elaine R Mardis; Richard K Wilson; Timothy J Ley
Journal:  Blood       Date:  2007-05-09       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.